GO
Loading...

A Crestor Day

Monday, 10 Nov 2008 | 6:18 PM ET

One of the weapons widely used to fight cholesterol might be more powerful than previously believed. Is there a trade here?

A new study concludes that AstraZeneca's cholesterol fighter Crestor slashed deaths, heart attacks, and strokes in healthy patients who took the drug as a preventative measure.

Talking Biotech: AZN
Insight on whether the biotech sector could see a bounce on a new study, with CNBC's Mike Huckman and the Fast Money team.

The impressive results have won the attention of doctors around the world with some now suggesting it could change the way we treat this disease.

"It's a landmark study. I think it's going to very much change the concept of primary prevention," Dr Christie Ballantyne of Methodist DeBakey Heart and Vascular Center in Houston said in an interview.

In a first on CNBC interview AstraZeneca CEO David Brennan said the results should have a significant effect on sales.

And CNBC’s Mike Huckman thinks the results will have a substantial ripple effect, creating a significant impact on companies like Quest Diagnostics that perform the tests to determine cholesterol levels.

It’s unbelievably good news, adds Pete Najarain. AstraZeneca might be worth a look, but I’ve got my eye on Amgen because they have as many as 5 blockbuster drugs in the pipeline. Also I like Johnson & Johnson , Novartis and Myriad Genetics in the space.

Don’t forget Celegene, adds Guy Adami. They have no debt and a great balance sheet.

Read More:

> AstraZeneca CEO on Crestor Study

______________________________________________________
Got something to to say? Send us an e-mail at fastmoney-web@cnbc.com and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send your e-mail to fastmoney@cnbc.com.

Trader disclosure: On Nov.10, 2008, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Adami Owns (AGU), (BTU), (C), (GS), (INTC), (MSFT), (NUE); Macke Owns (SDS), (MCD), (WMT), (BNI), (UUP), (MSFT); Macke Is Short (BBY); Najarian Owns (BBY) Put Spread; Najarian Owns (SBUX) Puts; Najarian Owns (CHK) Call Spread; Seymour Owns (AAPL), (BAC), (F), (MER), (BX); Seygem Asset Management Owns (PTR)

  Price   Change %Change
AMGN
---
AZN
---
CELG
---
JNJ
---
MYGN
---
NOVN
---

Featured

Contact Fast Money

  • Showtimes

    Halftime Report - Weekdays 12p ET
    Fast Money - Weekdays 5p ET
  • Melissa Lee is the host of CNBC's “Fast Money” and “Options Action.”

  • Scott Wapner is host of the "Fast Money Halftime Report," which airs weekdays from 12 p.m. to 1 p.m. ET.

  • Guy Adami is a contributor on CNBC's "Fast Money." He also is managing director of stockMONSTER.com.

  • Najarian, the "Pit Boss," is cofounder of optionMONSTER.com, a news site for options traders.

  • Finerman is president of Metropolitan Capital Advisors, Inc., a company she co-founded.

  • Founder of EmergingMoney.com

  • Chief Market Strategist for Virtus Investment Partners & CNBC Contributor

Halftime Report